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IL (interleukin)-6, an established growth factor for multiple
myeloma cells, induces myeloma therapy resistance, but the
resistance mechanisms remain unclear. The present study
determines the role of IL-6 in re-establishing intracellular
redox homoeostasis in the context of myeloma therapy. IL-6
treatment increased myeloma cell resistance to agents that induce
oxidative stress, including IR (ionizing radiation) and Dex
(dexamethasone). Relative to IR alone, myeloma cells treated
with IL-6 plus IR demonstrated reduced annexin/propidium
iodide staining, caspase 3 activation, PARP [poly(ADP-
ribose) polymerase] cleavage and mitochondrial membrane
depolarizationwithincreasedclonogenicsurvival.IL-6combined
with IR or Dex increased early intracellular pro-oxidant levels
that were causally related to activation of NF-κB (nuclear factor
κB) as determined by the ability of N-acetylcysteine to suppress
both pro-oxidant levels and NF-κB activation. In myeloma
cells, upon combination with hydrogen peroxide treatment,
relative to TNF (tumour necrosis factor)-α, IL-6 induced an
early perturbation in reduced glutathione level and increased
NF-κB-dependent MnSOD (manganese superoxide dismutase)
expression. Furthermore, knockdown of MnSOD suppressed the
IL-6-induced myeloma cell resistance to radiation. MitoSOX Red
staining showed that IL-6 treatment attenuated late mitochondrial
oxidant production in irradiated myeloma cells. The present
study provides evidence that increases in MnSOD expression
mediateIL-6-inducedresistancetoDexandradiationinmyeloma
cells. The results of the present study indicate that inhibition of
antioxidant pathways could enhance myeloma cell responses to
radiotherapy and/or chemotherapy.
Keywords:dexamethasone,interleukin-6,manganesesuperoxide
dismutase (MnSOD), multiple myeloma, nuclear factor κB
(NF-κB), radiation therapy.
INTRODUCTION
MM (multiple myeloma) is a human B-cell neoplasm that
invariably shows an aggressive course in the clinic. Of the
various secreted cytokines, paracrine and autocrine regulation
by IL (interleukin)-6 plays a particularly important role in
myeloma cell proliferation and chemoresistance; high expression
levels are associated with aggressive disease and poor survival
rates [1]. IL-6 has been shown to induce superoxide (O2
•−)
production in neutrophils, monocytes [2] and neuronal cells
[3]. Paradoxically, IL-6 can induce adaptive responses to
oxidative stress in normal tissues by protecting pulmonary
alveolar cells from hydrogen peroxide (H2O2)-induced cell
death and preventing reperfusion injury in rats [4]; transgenic
mice overexpressing IL-6 in lungs show resistance to hyperoxia
[5]. Despite the increasing evidence that IL-6-induced pro-
oxidant production could confer an adaptive response in normal
tissues, the relationship between IL-6-mediated resistance to
oxidative stress and myeloma cell resistance to therapy is
unknown.
In comparison with normal tissues, cancer cells thrive in a
pro-oxidant environment and are tolerant to oxidative stress [6].
Indeed,MMpatientsshowincreasedlipidperoxidationandlower
levels of antioxidant enzymes in plasma and erythrocytes [7–10].
MnSOD [manganese SOD (superoxide dismutase)] plays a major
role in maintaining cellular antioxidant capacity [11,12]. A role
for MnSOD in MM progression can be postulated as: (i) mice
lacking a copy of the Sod2 gene show an increased incidence
of spontaneous B-cell lymphomas [13]; and (ii) myeloma cells
express MnSOD protein at low levels [14,15]. NF-κB (nuclear
factor κB), a redox-regulated transcription factor [16], plays a
central role in regulating the growth and survival of MM [17].
Cytokines, such as TNF (tumour necrosis factor)-α and IL-1β,
have been shown to increase pro-oxidant production, NF-κB-
driven induction of SOD2 mRNA and the enzymatic activity of
MnSOD [18,19].
In the present study we show that IL-6 treatment augments
radiotherapy- and Dex (dexamethasone)-induced early pro-
oxidantlevels inmyeloma cells. AnIL-6-inducedresistanceto IR
(ionizing radiation) and Dex treatment was rendered by NF-κB-
driven MnSOD expression. These results support the hypothesis
that inhibition of antioxidant pathways could mitigate IL-6-
induced adaptive responses to radiotherapy and/or chemotherapy
in myeloma cells.
Abbreviations used: BM, bone marrow; CF, cleaved fragment; Dex, dexamethasone; DHE, dihydroethidium; E+, ethidium cation; GPx, glutathione
peroxidase; H2DCF-DA, 2 ,7 -dichlorodihydroﬂuorescein diacetate; ICCM, irradiated cell conditioned medium; IκB, inhibitor of NF-κB; IL, interleukin; IR,
ionizingradiation;JC-1,5,5 ,6,6 -tetrachloro-1,1 ,3,3 -tetraethylbenzimidazolylcarbocyanineiodide;KD,knockdown;MFI,meanﬂuorescenceintensity;MM,
multiple myeloma; MOI, multiplicity of infection; MnSOD, manganese superoxide dismutase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
bromide; NAC, N-acetylcysteine; NBD, NEMO (NF-κB essential modulator)-binding domain; NF-κB, nuclear factor-κB; NSF, normalized survival fraction;
2-OH-E+, 2-hydroxyethidium; PARP, poly(ADP-ribose) polymerase; PEG–SOD, poly(ethylene glycol)-conjugated superoxide dismutase; PI, propidium
iodide; qPCR, quantitative PCR; RLU, relative luciferase units; ROS, reactive oxygen species; shRNA, small hairpin RNA; SOD, superoxide dismutase;
TNF, tumour necrosis factor; Z-LEHD-FMK, benzyloxycarbonyl-Leu-Glu-His-DL-Asp-ﬂuoromethylketone; Z-VAD-FMK, benzyloxycarbonyl-Val-Ala-DL-Asp-
ﬂuoromethylketone.
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EXPERIMENTAL
Cell culture
The human BM (bone marrow) stromal cell line HS-5 (CRL-
11882)andmyelomacelllineRPMI-8226(8226,CCL-155)were
obtained from A.T.C.C. The MM.1S myeloma cell line was from
Dr Steve Rosen (Feinberg School of Medicine, Northwestern
University, Chicago, IL, U.S.A.) and HBME-1, a human BM
endothelial cell line, was from Dr Kenneth Pienta (Department
of Internal Medicine, University of Michigan, Ann Arbor, MI,
U.S.A.). All cell lines were grown in RPMI complete medium
as described previously [20]. For most experiments, cells were
pre-treated for 6 h with IL-6 (50 ng/ml, R&D Systems), prior to
exposure to IR (6 Gy, delivered using a Cs-137 source at a dose
rateof0.83Gy/min),andpost-culturedfordifferenttimeswithout
or with IL-6.
Clonogenic survival assay
Cellswereseededovernightincompletemediumin24-wellplates
(1×10
5 cells/well), and then treated with IL-6 and/or IR. For
adherent cells (HS-5 and HBME-1), 100 cells/well were seeded
in six-well plates (in triplicate) and cultured for 7 days. Colonies
were ﬁxed with 75% methanol/25% acetic acid, stained with
0.2% Coomassie Blue solution and the number of clonogenic
cells was assessed [21]. Clonogenicity of myeloma cells was
determined using the limiting dilution method [22]. Plating
efﬁciency and survival fractions were calculated as described
previously [20]. For each cell population, the NSF (normalized
survivalfraction),relativetothenumberofuntreatedcontrolcells,
was calculated.
Measurement of apoptosis
Viability and induction of cell death (early and late
apoptosis/necrosis) were examined by annexin-V–FITC/PI
(propidium iodide) dual staining of cells (Cayman Chemical)
followed by ﬂow cytometric analysis according to previously
published methods [23].
Apoptosis was also measured by a caspase 3 ﬂuorescence
assay (Cayman Chemical) as described previously [20]. Caspase
3 activity is expressed as units/mg of total protein.
Measurement of mitochondrial membrane potential was
performed using the JC-1 (5,5
 ,6,6
 -tetrachloro-1,1
 ,3,3
 -tetra-
ethylbenzimidazolylcarbocyanineiodide)dye(MolecularProbes,
Invitrogen) as described previously [20]. The cationic dye JC-1
accumulates and aggregates in intact mitochondria, emitting
a bright red ﬂuorescence, whereas, upon disruption of the
mitochondrial membrane potential, the monomeric dye emits
greenﬂuorescenceinthecytoplasm.Brieﬂy,cellswerepre-treated
with conditioned medium from irradiated HS-5 cells [ICCM
(irradiatedcellconditionedmedium),6Gycollected24 hpost-IR]
or IL-6 (1, 2.5, 10 or 50 ng/ml) for 6 h followed by irradiation. At
24 h post-treatment, cells were incubated with JC-1 dye (200 nM
f o r3 0m i n )a t3 7◦C in the dark and read using a ﬂuorescent plate
reader (Tecan) with excitation and emission wavelengths set at
485 and 595 nm respectively for red ﬂuorescence, and 485 and
535 nm respectively for green ﬂuorescence. For each condition,
triplicate samples were run, ﬂuorescent readings were corrected
for background, and the ratio of red signal to green signal was
calculated.
Immunoblotting
Protein immunoblotting was performed according to standard
protocols as described previously [20,23,24]. Cells were
seeded in complete medium in six-well culture plates
(1×10
6 cells/well) followed by IL-6 treatment and/or
irradiation. Alternatively, cells were treated for 2 h with
50 μM Z-LEHD-FMK (benzyloxycarbonyl-Leu-Glu-His-DL-
Asp-ﬂuoromethylketone; Sigma), ICCM, or anti-IL-6Rα
antibody (0.2 μg/ml, R&D Systems, 2 h pre-treatment of cells
beforeadditionofICCM).Totalcelllysatewasprepared24 hpost-
irradiation.Forthis,cellswerelysedusing1%NonidetP40buffer
(50 mM Tris/HCl, pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM
NaF,1 mMNa3VO4 and0.02%NaN3,30 minonice),centrifuged
at 14000 g for 10 min, and supernatants were collected. Protein
concentrations were determined using the Bio-Rad dye reagent
(Bio-Rad Laboratories), and 20–50 μg of protein per lane was
separated by SDS/PAGE (12.5% gels) and transferred to PVDF
membranes. Non-speciﬁc binding was blocked with 5% (w/v)
non-fat dried skimmed milk powder in TBST buffer (4 mM Tris
base, 100 mM NaCl, pH 7.5, and 0.1% Tween 20) and incubated
overnight at 4 ◦C, with primary antibodies against MnSOD,
PARP [poly(ADP-ribose) polymerase]-CF (cleaved fragment),
IκBα (inhibitor of NF-κB α), tubulin (all from Cell Signaling
Technology) or GAPDH (glyceraldehyde-3-phosphate denydro-
genase, Imgenex), and then incubated with secondary antibody
for 1 h at room temperature (25◦C). Blots were developed by
enhanced chemiluminescence assay (Thermo Scientiﬁc). Bands
were visualized by autoradiography and then analysed using
Image J 1.38x software (http://rsbweb.nih.gov/ij/index.html). For
illustrations,AdobePhotoshopCS4wasusedwhereFigureswere
converted into greyscale, cropped, and then contrast-corrected
using Photoshop’s ‘Auto Contrast’ tool.
Detection of intracellular ROS (reactive oxygen species)
Intracellular oxidants, such as ROS, were detected using the
oxidation-sensitive ﬂuorescent probe dye carboxy-H2DCF-DA
(carboxy-2
 ,7
 -dichlorodihydroﬂuorescein diacetate, Invitrogen)
[20]. Cells were seeded overnight in 96-well plates and treated
for 2 h with IL-6 (1, 2.5, 10 or 50 ng/ml), IL-6 (50 ng/ml) plus
irradiation, TNF-α (2.5 ng/ml), IL-1β (1 ng/ml), Dex (1 μM) or
Dex plus irradiation. Speciﬁc wells were pre-treated with NAC
(N-acetylcysteine) before treatments. Samples were incubated
with H2DCF-DA (10 μg/ml, 30 min) and ﬂuorescence was
measured (Tecan; λex =495 nm, λem =530 nm).
DHE (dihydroethidium) was used to measure IL-6, IR and/or
Dex-induced formation of intracellular oxidants. Speciﬁcally,
myeloma cells were incubated with DHE (10 μM, Invitrogen)
at 37◦C for 30 min (Phenol-Red-free RPMI 1640 medium
containing 5 mM pyruvate) followed by treatment with IL-6 or
IR (0.5, 1 or 2 h), IL-6 plus IR (2 h) or Dex (2 h). Formation of
2-OH-E
+ (2-hydroxyethidium) was preferentially detected using
ﬂow cytometry with λex =405 nm and λem =585 nm [25]. For
each sample, the MFI (mean ﬂuorescence intensity) of 10000
live cells was analysed and corrected for autoﬂuorescence against
the control untreated cells.
Changes in the mitochondrial oxidant production were
measured using MitoSOX Red staining (5 mM for 15 min at
37◦C, Invitrogen) followed by ﬂow cytometry (λex =488 nm
and λem =585 and 542 nm) [26]. The speciﬁcity of DHE and
MitoSOX staining was conﬁrmed using PEG–SOD [poly
(ethylene glycol)-conjugated SOD; 100 units/ml, 2 h before
treatments] or antimycin A treatment (100 μMf o r2 h ) .
Alternatively,myelomacellsweretreatedwithoutorwithZ-VAD-
FMK (benzyloxycarbonyl-Val-Ala-DL-Asp-ﬂuoromethylketone;
Sigma, 100 μM for 2 h [23]) followed by IL-6 and/or IR
treatments and cultured for 36 h in 96-well plates. Cells were
washed with PBS (137 mM NaCl, 10 mM phosphate and 2.7 mM
c   The Authors Journal compilation c   2012 Biochemical Society © 2012 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.IL-6-mediated redox regulation of multiple myeloma 517
KCl, pH 7.4) and incubated with MitoSOX Red (5 μM, ﬁnal
concentration) at 37◦C for 10 min. Fluorescence intensity was
measured at 510/580 nm using a plate reader (Tecan). The
experiment was repeated twice, and run in triplicate for each
treatmentcondition.ThemeanintensityofMitoSOXﬂuorescence
was normalized with that in control untreated cells, and the
fold change in intensity in the context of treatments was
calculated. The presence of intracellular 2-OH-E
+ was also
veriﬁed using HPLC following the method of Zielonka et al.
[25] and is described in the Supplementary Experimental section
(at http://www.BiochemJ.org/bj/444/bj4440515add.htm).
For confocal microscopy, at 36 h post-treatment, cells were
suspended in PBS containing MitoSOX Red (5 μM) and
MitoTracker Green (50 nM, Invitrogen), and incubated at 37◦C
for 30 min. Cells were gently washed with warm PBS and live
imaging was performed using a Leica spinning-disk confocal
microscope equipped with a Hamamatsu EM-CCD (charged-
coupled-device) digital camera (Hamamatsu Photonics) and
the ‘Metamorph’ image acquisition and processing software
(Molecular Devices). All images were acquired using a 63×
1.3 NA (numerical aperture) objective. In these experiments,
all photomicrographs were exposed and processed identically
for a given ﬂuorophore. Images were corrected for background
ﬂuorescence using unlabelled specimens. For double-labelling
experiments, control samples were labelled identically with the
individual ﬂuorophores, and exposed identically with the dual-
labelled samples at each wavelength, to verify that there was no
signal crossover from different emission channels at the exposure
settings used.
GSH assay
Cells were seeded into six-well plates (1×10
5/ml) in complete
medium for 12 h, and were either left untreated or were treated
with IL-6 (2.5 or 50 ng/ml) or TNF-α (2.5 or 10 ng/ml), for 4, 10
or 24 h. At completion of the treatment time, cells were pelleted
(800 g for 5 min at 4◦C), rinsed once with PBS and resuspended
in metaphosphoric acid (5 min at room temperature, 100 mg/ml;
Sigma).Thesupernatantwascollectedbycentrifugation(18000 g
for3 min),neutralizedwith4 Mtriethanolamine(Sigma)andused
to estimate total GSH (Cayman Chemical). Each sample (20 μl)
was diluted in 2× Mes buffer (0.4 M Mes, 0.1 M phosphate and
2 mM EDTA, pH 6.0) and absorbance was measured at 5 min
intervalsfor30 min(Tecan,405–414 nM).TheGSHassaykituses
an enzymatic recycling method, measuring the TNB (5-thio-2-
nitrobenzoic acid) generated in the presence of GSH reductase to
estimatetotalGSHinthesample.Theproteinpelletwasdissolved
in 1 M NaOH and used for protein estimation. All assessments of
glutathione levels were normalized to the protein content and are
expressed as nmoles of total GSH/mg of protein.
Adenoviral transduction
Cells (3×10
5 cells/well) were seeded overnight in 24-well plates
in complete medium. Recombinant adenovirus was added in
serum-free medium, centrifuged for 30 min at 25◦C, and then
incubated for 2 h at 37◦C. Cells were allowed to recover for
48 h in complete medium. For all cell lines, the adenovirus
transduction efﬁciency was >80%, as assessed by measurement
of Ad-CMV-GFP reporter gene expression (results not shown).
Adenoviruses expressing human MnSOD cDNA (Ad-MnSOD),
control (Ad-CMV), Ad-IκBα(S32A/S36A) (also referred to as
Ad-IκBα-DN), and NF-κB-driven luciferase reporter (Ad-NF-
κB Luc) were obtained from the Gene Transfer Vector Core at the
University of Iowa. For all recombinant adenoviral constructs,
a MOI (multiplicity of infection) of 100 was used, except for
Ad-IκBα-DN, where a MOI of 10 was used.
Reporter gene assay
Cells were transduced with Ad-NF-κB Luc for 48 h and then
treated with IL-6 (50 ng/ml), TNF-α (2.5 ng/ml), H2O2 (100 μM)
and/or IR. At 4 h post-irradiation, the cells were lysed in 1%
Triton X-100 buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-
100 and 10 mM EDTA, pH 7.2), and luciferase was measured
using the Luc assay (Promega). To assess whether IR- and/or
IL-6-induced redox changes up-regulate Ad-NF-κB Luc activity,
MM.1S cells were pre-treated with or without NAC (10 mM for
1 h) and stimulated with IL-6 and/or IR for 4 h followed by the
Luc assay. The level of reporter gene expression was presented as
RLU (relative luciferase units)/mg of total protein.
Generation of stable SOD2 KD (knockdown) myeloma cells
An shRNA (small hairpin RNA) subcloned into the pLKO.1
lentivirus (Open Biosystems, RHS4533) was used to generate
myeloma cells in which the SOD2 gene was stably knocked
down.Virusparticlesweregeneratedbyco-transfectingtheSOD2
shRNA-expressing plasmid, envelope plasmid (pMD2.G), and
packagingplasmid(pCMV-dR8.91)intoHEK(humanembryonic
kidney)-293T cells using Lipofectamine
TM 2000 (Invitrogen).
Virus-containing supernatants were collected at 48 h, ﬁltered
through a 0.45 μM ﬁlter, and used to transduce MM.1S or 8226
cells in the presence of polybrene (8 μg/ml, Sigma). At 24 h, the
medium was replaced and the stable cell population was enriched
with puromycin (2 μg/ml) for 2 weeks. The new cell lines were
expanded, and MnSOD KD was conﬁrmed by immunoblotting
and activity assays.
MnSOD activity assay
MnSOD activity in whole-cell lysates was measured after
treatment with IL-6 and/or IR, in the absence or presence of NBD
[NEMO (NF-κB essential modulator)-binding domain; 50 μM
for 2 h; Imgenex) peptide or Ad-IκBα(S32A/S36A), using a kit
(CaymanChemical).Thisassayisbasedontetrazoliumsalt-based
detection of O2
•− generated by xanthine oxidase and hypoxanth-
ine. One unit of MnSOD is deﬁned as the amount of protein
needed to achieve 50% inhibition of O2
•−-mediated reduction
of the tetrazolium salt in the presence of potassium cyanide
(2.5 mM for 30 min pre-incubation prior to running the assay).
The absorbance was read at 450 nm and enzyme activities were
expressedasspeciﬁcactivity(unitsofactivity/mgoftotalprotein).
qPCR (quantitative PCR)
Cells were incubated with IL-6 (50 ng/ml), TNF-α (2.5 ng/ml) or
IL-1β (1 ng/ml), and cultured for 10 h. Alternatively, cells were
pre-treatedwithIL-6,irradiatedandthenfurtherculturedfor10 h.
Total RNA was isolated using a Qiagen RNeasy kit (Qiagen) and
quantiﬁed. cDNA was synthesized from 800 ng of total RNA,
using the iScript cDNA synthesis kit (Bio-Rad Laboratories).
Thermocycler conditions included a 5 min incubation at 25◦C,
a 30 min incubation at 42◦C, and a 5 min incubation at 85◦C.
The cDNAs were subjected to qPCR analysis with the following
5
 →3
  primers (sense and antisense respectively): SOD2, GCCT-
GCACTGAAGTTCAATGG and GCTTCCAGCAACTCCCC-
TTT, amplicon length 105 bp; catalase, TTCGGTTCTCCACT-
GTTGCTG and AATTTCACTGCAAACCCACGA, amplicon
length 76 bp; GPx (glutathione peroxidase)-1, AACGAT-
GTTGCCTGGAACTTTG and GAAGCGGCGGCTGTACCT,
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amplicon length 79 bp; and human 18S, CCTTGGATGTGGTA-
GCCGTTT and AACTTTCGATGGTAGTCGCCG, amplicon
length 105 bp. Primers were designed using the Primer Express
software (Applied Biosystems). The assay was performed in a
96-well optical plate, with a ﬁnal reaction volume of 20 μl,
including synthesized cDNA (20 ng), oligonucleotide primers
(100 μM each), and 2× SYBR Green/ROX PCR master mix
(Bio-Rad Laboratories). Samples were run on an ABI PRISM
Sequence Detection System (model 7000, Applied Biosystems).
PCR conditions were 50◦Cf o r2 m i n ,9 5 ◦Cf o r2 m i na n d
30 s, 95◦C for 15 s, and 60◦C for 1 min for 40 cycles. Results
were analysed using the ABI PRISM 7000 SDS software. The
denaturation and annealing steps were carried out for 40 cycles to
determine the threshold cycle (CT) values for all of the genes
analysed. Samples were checked for non-speciﬁc products or
primer/dimer ampliﬁcation by melting curve analysis. The CT
values for the target genes in all of the samples (analysed in
triplicate) were normalized on the basis of the abundance of the
18S transcript, and the fold difference (relative abundance) was
calculated using the formula 2
−  CT and was plotted as the mean
(n=3).
Statistical analysis
Results in histograms represent means+ −S.D. Statistical analysis
using Student’s t test or one-way ANOVA followed by Student-
Newman Keuls t test were performed. P<0.05 was considered
to be statistically signiﬁcant.
RESULTS
IL-6 confers radioresistance in myeloma cells
Inourpreviousstudy,usingmyeloma–BMstromalcellco-culture,
we showed that paracrine IL-6 inhibits irradiation-mediated
killing of myeloma cells [20]. To determine whether addition
of exogenous IL-6 inhibits myeloma cell killing by irradiation,
clonogenic cell survival assays were performed. Irradiation alone
reduced the clonogenic survival of myeloma cells and BM
accessory cells by 40–50% (Figure 1A). Notably, IL-6 plus IR
increased clonogenicity of myeloma cells but did not affect the
radiosensitivityofHS-5orHBME-1cells(Figure1A),suggesting
that IL-6 induces radioresistance in myeloma cells. Next, various
parameters indicative of apoptosis were evaluated at 24 h post-IR
without or with treatment with IL-6. In annexin V/PI staining,
IL-6 reduced IR-induced apoptosis from 43% to 17% and 22%
to 8% in MM.1S and 8226 cells respectively (Figure 1B). The
pan-caspase inhibitor Z-VAD-FMK signiﬁcantly interfered with
IR- or IL-6 plus IR-induced apoptosis (results not shown). IR led
to 2.4-fold and 1.3-fold increases in the activation of caspase 3 in
the MM.1S and 8226 cells respectively, which was inhibited by
IL-6 (Figure 1C). Also, IL-6 inhibited the p85 PARP cleavage
induced by IR (Figure 1D, panel i). Since the HS-5 cell line has
been shown to secrete IL-6 [27], we next determined whether the
conditioned mediumfromirradiated HS-5 cells(ICCM) similarly
protects myeloma cells from IR-induced apoptosis, as seen with
the addition of exogenous IL-6. Using an ELISA assay, the IL-6
concentration in the HS-5 culture supernatant with 6 Gy of
radiationtreatmentat24 hwasdetectedas3.5+ −0.2 ng/mlrelative
to 1.9+ −0.1 ng/ml for untreated cells. For MM.1S and 8226 cells,
irradiation resulted in PARP cleavage at 24 h, which was blocked
by pre-treatment with a caspase 9 inhibitor (Figure 1D, panel
ii). Notably, in both MM.1S and 8226 cells, radiation-induced
PARP cleavage at 24 h was partially blocked by 6 h of pre-
incubation with ICCM and blocking of the ligand-binding IL-6
receptor α-chain abrogated the radioprotective effect of ICCM
on myeloma cells (Figure 1D, panel ii). To further conﬁrm that
radiation-induced apoptosis is prevented by ICCM or exogenous
IL-6, the relative changes in mitochondrial membrane potential
were measured using JC-1 dye. At 24 h post-treatment, both
MM.1S and 8226 cell lines showed a drop in mitochondrial
membrane potential (indicated by a decrease in the ratio of red
signaltothegreensignal)withirradiation,whichwassigniﬁcantly
inhibited by pre-treatment with ICCM or IL-6 (Figure 1E). To
determine whether exogenous IL-6 protects IR-induced myeloma
cell apoptosis in a dose-dependent fashion, cells were treated
with IL-6 (1, 2.5, 10 or 50 ng/ml for 2 h) followed by irradiation,
and JC-1 staining was performed at 24 h. For both MM.1S and
8226 cells, all IL-6 concentrations, except 1 ng/ml, inhibited IR-
induced mitochondrial depolarization (Figure 1F). Cumulatively,
Figure 1 shows that exogenous IL-6 at concentrations of 2.5,
10 or 50 ng/ml protects myeloma cells from irradiation-induced
apoptosis.
IL-6 stimulates ROS generation by IR and Dex in myeloma cells
We have previously shown that irradiation induces ROS
production in myeloma cells [20]. Given that IL-6 can also
increase intracellular O2
•− levels [2,3], we next determined
whether IL-6 treatment alters irradiation-mediated perturbations
in pro-oxidant levels in myeloma cells. Treatment with IL-6
or IR for 2 h increased H2DCF-DA oxidation, and IL-6 plus
IR enhanced this response (Figure 2A). The effects of IL-6
and/orIRonH2DCF-DAoxidationwereabrogatedwithtreatment
with the thiol antioxidant NAC (Figure 2A). To assess whether
combined treatment with IL-6 plus IR results in an increased
steady-statelevelofintracellularpro-oxidants(presumablyO2
•−)
at 2 h, the oxidation-sensitive DHE probe was used and ﬂow
cytometry was performed as described by Robinson et al. [28]. In
MM.1S cells, IL-6 and IR treatment resulted in a 2.2+ −0.4- and
1.7+ −0.2-fold increase in DHE oxidation relative to the control,
which was set to 1 (Figure 2B). Notably, combined treatment
of IL-6 plus IR resulted in a 2.4+ −0.2-fold increase in DHE
oxidation, which was higher compared with treatment with IL-
6 or IR (Figure 2B). A time kinetic study of DHE oxidation in
MM.1S cells by IL-6 or IR treatment showed that IL-6 steadily
increased DHE oxidation for 2 h and IR induced DHE oxidation
for 2 h, yet a maximum DHE oxidation was noted at 1 h post-
irradiation (Supplementary Figures S1A and S1B respectively
at http://www.BiochemJ.org/bj/444/bj4440515add.htm). Since a
lower concentration of IL-6 was detected in the supernatant
of irradiated HS-5 cells, a dose-dependent production of pro-
oxidantswiththeadditionofexogenousIL-6wasinvestigated.For
MM.1Sand8226cells,IL-6treatment(2.5,10or50 ng/mlfor2 h)
resulted in an increased H2DCF-DA oxidation (Supplementary
Figure S1C), demonstrating that both physiological and high
levels of IL-6 treatments increase the steady-state levels of
intracellular pro-oxidants in myeloma cells.
Previous reports have shown a limited speciﬁcity of
hydroethidine-based ﬂuorigenic probes for detecting intracellular
O2
•− [25,26,29]. To corroborate DHE oxidation results, HPLC
analysis of O2
•−-speciﬁc DHE oxidation was performed. IL-
6 treatment did not result in increased oxidation of DHE to
2-OH-E
+ when compared with untreated controls (results not
shown). When 8226 cells were treated with antimycin A, which
inhibits complex III of the mitochondrial electron transport chain
thereby generating O2
•−, HPLC analysis predominantly showed
theproductionofE
+ (ethidiumcation)(SupplementaryFigureS2
athttp://www.BiochemJ.org/bj/444/bj4440515add.htm).Quantit-
ative analysis of the one- and two-electron oxidation products of
DHE with antimycin A treatment indicate that DHE oxidation
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Figure 1 IL-6 protects myeloma cells from irradiation-induced apoptotic cell death
(A) Clonogenic survival of myeloma (MM.1S, 8226) or BM accessory cells (HS-5, HBME-1) cells treated with IL-6 (50ng/ml) and/or IR (6 Gy) and normalized to untreated control cells. Values
representthemeanofthreereplicates+ −S.D.*P <0.05comparedwithIR;ns,notsigniﬁcant.(B)Percentageofviable,apoptoticandnecrotic/lateapoptoticcellpopulationsinmyelomacellstreated
withIL-6(50ng/ml)and/orIRandassessedbyﬂowcytometryat24h.Resultsshownarefromoneexperiment,andrepresentativeofthreeindependentexperiments.  P <0.001.neg,negative;pos,
positive. (C) Caspase 3 activity in myeloma cells treated with IL-6 (50ng/ml) and/or IR at 24 h. Values represent the mean of three replicates+ −S.D.  P <0.001 and ζP <0.01 compared with IR.
(D)RepresentativelevelsofPARP-CFandloadingcontrol(tubulin)inwhole-celllysatesofmyelomacellsat24h(i)treatedwithIL-6(50ng/ml)and/orIRor(ii)incontrolorirradiatedmyelomacells
treated with the caspase 9 inhibitor (Z-LEHD-FMK), ICCM and/or IL-6Rα-blocking antibodies. Band intensities relative to respective tubulin controls are shown above each blot. Immunoblotting
results are from one experiment, and representative of two independent experiments. JC-1 ﬂuorescence at 24h in myeloma cells pre-treated with (E) ICCM or IL-6 (50ng/ml) followed by irradiation,
or (F) IL-6 (0, 1, 2.5, 10 or 50ng/ml) followed by irradiation. The average JC-1 red/green ﬂuorescent ratio relative to the control (non-irradiated with medium alone) is shown. *P <0.01 compared
with IR. Two experiments were conducted and results from one experiment are shown.
in myeloma cells leads to approximately 100-fold more E
+
than 2-OH-E
+. At this stage, it remains speculative whether
the chemistry of DHE and 2-OH-E
+ and the formation of other
oxidationproducts,e.g.dimersofE
+ or2-OH-E
+,ore v enmix ed
dimers of E
+ and 2-OH-E
+, results in an ‘under-reporting’ of
formation of 2-OH-E
+. Nevertheless, the results using oxidation-
sensitive ﬂuorescent probes (H2DCF-DA and DHE) suggest that
IL-6treatmentresultsinincreasedintracellularlevelsofearlypro-
oxidant production in myeloma cells that is further augmented
with irradiation.
We have previously reported that Dex treatment exerts an
anti-myeloma effect by promoting the production of O2
•− and
H2O2 [20]. We next determined whether the protective role of
IL-6 on IR-mediated myeloma cell killing could be extended
to Dex-induced therapy resistance in MM. Treatment with Dex
increased H2DCF-DA oxidation, and this effect was enhanced
by the combination of IL-6 and Dex (Figure 2C). A kinetic
study over time showed a steady increase in DHE oxidation
with Dex treatment with approximately a 2-fold increase in
DHE oxidation at 2 h (Supplementary Figure S3A at http://www.
BiochemJ.org/bj/444/bj4440515add.htm). In the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] as-
say, IL-6 signiﬁcantly inhibited Dex-mediated myeloma cell
killing (Supplementary Figure S3B). This is consistent with
IL-6 as an established inhibitor of anti-myeloma activity of
glucocorticoids, including Dex [1], and agrees with the observed
IL-6-induced radioresistance in myeloma cells (Figure 1).
Besides IL-6, TNF-α and IL-1β promote the survival and
proliferation of myeloma cells, and also trigger pro-oxidant
production [30,31]. We therefore measured the levels of pro-
oxidant generated in response to TNF-α and IL-1β treatments
and compared this with IL-6 exposure. In myeloma cells, TNF-α
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Figure 2 IL-6 increases early steady-state levels of intracellular pro-oxidants generated by radiation or Dex treatment and H2DCF-DA oxidation by IL-6,
TNF-α or IL-1β
(A) Myeloma cells were treated with IL-6 (50ng/ml) and/or IR (without or with NAC) and H2DCF-DA oxidation was measured at 2 h. *P <0.05 or  P <0.001 compared with control, ζP <0.005
compared with IR treatment alone. (B) MM.1S cells were treated with IL-6 (50ng/ml) and/or IR and DHE oxidation was measured after 2 h by ﬂow cytometry. Histograms with MFI values are shown
from one experiment, and are representative of two independent experiments. For each histogram, the x axis and y axis show the percentage of cells and DHE oxidation respectively. (C) Myeloma
cells were treated with IL-6 (50ng/ml) and/or Dex, and H2DCF-DA was measured at 2h. The values represent the means+ −S.D. from three replicates and are normalized to the untreated control.
*P <0.05 or  P <0.001 compared with the control, ζP <0.05 compared with Dex treatment alone. (D)H 2DCF-DA oxidation after 2h in myeloma cells treated with IL-6 (50ng/ml), TNF-α
(2.5 ng/ml) or IL-1β (1ng/ml). Means+ −S.D. from three replicates is shown.  P <0.005 or ζP <0.001 compared with the control.
induced a more robust ROS production than IL-6, whereas IL-1β
only marginally increased the H2DCF-DA oxidation (Figure 2D).
TheselectedconcentrationsofIL-6(50 ng/ml),TNFα (2.5 ng/ml)
or IL-1β (1 ng/ml) supported myeloma cell proliferation, as
conﬁrmed by the MTT assay (results not shown).
Overall,inmyelomacells,IL-6treatmentwasfoundtoincrease
early pro-oxidant levels and potentiate overall ROS production
induced by irradiation or Dex treatments. Strikingly, as seen
in Figure 1, IL-6 treatment increased clonogenic survival of
myeloma cells and also decreased the cytotoxicity of IR and
Dex. Taken together, the results of Figures 1 and 2 show that
the elevated early ROS production by combination therapy is not
cytotoxictomyelomacells,andthatIL-6treatmentmaysomehow
prime myeloma cells to resist the oxidative stress-induced cell
killing.
IL-6 and TNF-α differentially regulate H2O2-mediated NF-κB
activation, apoptotic cell death and steady-state levels of GSH in
myeloma cells
NF-κB is a redox-regulated transcription factor where diverse
stimuli that appear to utilize ROS can act as common effectors for
activating NF-κB [16]. Since treatment with pro-inﬂammatory
cytokines (TNF-α and IL-6) and anti-myeloma therapeutic
agents (IR and Dex) induced early ROS production in myeloma
cells, we assessed whether increased pro-oxidant production
by these agents was associated with NF-κB activation. Studies
were conducted where oxidative stress was produced by H2O2
treatment. Similar to IR, H2O2 treatment produces different
types of ROS, i.e. O2
•−,H 2O2 and hydroxyl radicals, which
are capable of damaging DNA, protein and lipid membranes
in cells [32]. Myeloma cells were treated with IL-6, TNF-α
and/or H2O2,a n dN F - κB activity was measured at 4 h using
an adenoviral-delivered NF-κB reporter assay. Relative to IL-
6, TNF-α treatment resulted in a more pronounced increase in
NF-κB activation (Figure 3A). When cytokine treatment was
combined with H2O2,a ni n c r e a s ei nN F - κB activation was noted
for IL-6, whereas combination of TNF-α with H2O2 resulted in
an attenuation of NF-κB activity (Figure 3A).
We next assessed whether TNF-α treatment inhibits myeloma
cell death induced by oxidative stressors, as seen for IL-6
when combined with IR or Dex treatments. For this, activated
caspase 3, as a biochemical marker of apoptosis, was measured
at 24 h in myeloma cells treated with TNF-α or IL-6 in the
presence or absence of H2O2. In myeloma cells, treatment with
H2O2 resulted in activation of caspase 3; this was signiﬁcantly
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Figure 3 IL-6 and TNF-α differentially regulate H2O2-induced-oxidative-
stress-mediated NF-κB activation, apoptotic cell death and steady-state
levels of GSH in myeloma cells
Myeloma cells were treated with IL-6 (50ng/ml) or TNF-α (2.5ng/ml) alone or in combination
with H2O2 (100μM) and (top panel) NF-κB-driven luciferase activity was measured at 4 h.
Values are depicted as the fold change in mean RLU+ −S.D., n=3, normalized to protein
concentration. *P <0.001 or  P <0.005 compared with control, ϕP <0.01 compared with
IL-6 or ζP <0.001 compared with TNF-α. Middle panel, myeloma cells were treated as in
the top panel and caspase 3 activity was measured at 24h. Values represent averages of three
replicates+ −S.D. *P <0.001 compared with H2O2,  P <0.05 compared with H2O2. Bottom
panel, intracellular GSH levels in 8226 cells, measured at 4, 10 or 24h following treatment
with IL-6 (2.5 or 50ng/ml) or TNF-α (2.5 or 10ng/ml). Total GSH was measured using the
spectrophotometric recycling assay and fold change relative to each time point was calculated.
Values represent the mean of three runs+ −S.D. *P <0.001 compared with the 4h control,
 P <0.001 compared with the 10h control and ϕP <0.001 compared with the 24h control.
blocked by IL-6 treatment, whereas only a slight rescue in
H2O2-mediated activation of caspase 3 was noted with TNF-α
treatment (Figure 3B). Thus TNF-α is not as effective as
IL-6 in protecting myeloma cells from H2O2-mediated oxidative
cell death (Figure 3B).
Among intracellular antioxidant molecules, GSH is the most
abundant non-protein thiol and constitutes the ﬁrst-line defence
against oxidative injury [33,34]. Furthermore, pro-inﬂammatory
cytokines, such as IL-6 [35,36] and TNF-α [37], have been
shown to regulate GSH synthesis in normal and cancer cells. We
thereforeinvestigatedhowtheintracellularGSHpoolinmyeloma
cells is perturbed by these cytokines. In 8226 cells, treatment
with IL-6 (2.5 or 50 ng/ml) for 4 h resulted in a decrease in
total intracellular GSH, whereas IL-6 treatment for 10 h or 24 h
showed a trend towards an overall increase in the steady-state
levels of GSH (Figure 3C). TNF-α treatment (2.5 or 10 ng/ml)
resulted in a sustained decrease in GSH levels at 4, 10 and 24 h
(Figure 3C). The GSH kinetics over time with IL-6 and TNF-α
was repeated in MM.1S cells, where IL-6 treatment showed a
transient early decrease in GSH levels, whereas TNF-α treatment
showeddecreasedtotalGSHlevelsupto24 h(resultsnotshown).
Overall, Figure 3 shows that simultaneous treatment with IL-6
and H2O2 increases NF-κB activation, protects myeloma cells
fromH2O2-mediatedoxidativecelldeath,andresultsinatransient
earlydecreaseinGSHlevels.Onthebasisofresultsobtainedwith
TNF-α, we speculate that TNF-α plus H2O2 treatment results in
an overall oxidized intracellular environment in myeloma cells
that could result in NF-κB inactivation. Indeed, studies have
shownacomplexredoxregulationofNF-κBactivationthatcanbe
modulatedbymultiplekinase(s)andphosphatase(s).Studieshave
shown that a reduced intracellular environment favours NF-κB
activation [38], and redox changes mediated by TNF-α treatment
can inhibit NF-κB activity [39].
IL-6 and IR treatment augment NF-κB activation, MnSOD activity
and mRNA expression in myeloma cells
To understand IL-6-mediated therapy resistance in myeloma
cells, we next determined whether treatments with IL-6 and/or
IR leads to alterations in NF-κB activation as seen with IL-
6p l u sH 2O2 treatment. In the NF-κB-luc assay, IR and IL-6
treatmentsindependentlyincreasedtranscriptionalactivityofNF-
κB at 4 h, and this effect was increased additively with IL-6 plus
IR (Figure 4A). Pre-incubation with NAC abrogated increases
in NF-κB activity, suggesting that IL-6- and IR-mediated early
activation of NF-κB were occurring by increased steady-state
levels of pro-oxidants.
Previous studies have shown that an intronic NF-κB element is
critical in driving expression of the SOD2 mRNA [18]. MnSOD
protein expression was thus determined after IL-6 (50 ng/ml)
and/or IR treatments. For both MM.1S and 8226 cells, IL-6
or IR treatments increased MnSOD protein expression, which
was further increased by IL-6 plus IR (Figure 4B). A dose–
response curve with IL-6 (2.5 or 10 ng/ml) showed that the
lower concentrations of IL-6 also induced MnSOD protein
expression in myeloma cells (Supplementary Figure S4A at
http://www.BiochemJ.org/bj/444/bj4440515add.htm).
To determine whether the increased MnSOD protein levels
correspond to increased enzymatic activity, myeloma cells were
treated with IL-6 and/or IR in the absence or presence of the
NBD peptide (which inhibits NF-κB by targeting the IκBk i n a s e
complex). Treatments with IL-6 or IR induced an increase in
MnSOD activity that was attenuated by NBD (Figure 4C).
Furthermore, IL-6 plus IR treatment mediated an increase
in MnSOD activity, which was signiﬁcantly higher than that
producedbyIRalone,andwasinhibitedbyNBD(Figure4C).The
NF-κB-inhibitory effect of NBD was conﬁrmed using Ad-NF-
κB-Luc reporter (Supplementary Figure S4B). NBD treatment
was, however, found to attenuate both constitutive and ROS-
induced MnSOD activity. To further conﬁrm whether inducible
NF-κB activity results in MnSOD up-regulation, Ad-IκBα-DN
was used, which effectively inhibited IL-6- and IR-induced NF-
κB activation (Supplementary Figure S4C) with a corresponding
increaseinIκBα proteinexpression(SupplementaryFigureS4D).
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Figure 4 IL-6 and/or IR treatment results in NF-κB-driven MnSOD expression and clonogenic survival
(A) Myeloma cells were treated with IL-6 (50ng/ml) and/or IR, and Luc activity was measured at 4h. Results depict the mean RLU+ −S.D., n=3, normalized to protein concentration. *P <0.05
compared with the control,  P <0.005 compared with IR treatment alone. (B) Myeloma cells were treated with IL-6 (50ng/ml) and/or IR for 24h and the whole-cell extract was probed with
anti-MnSOD or anti-tubulin antibodies. The quantiﬁcation of three independent experiments, expressed as the ratio between MnSOD and tubulin levels, after normalization to untreated control is
shown above each band. MnSOD activity at 24h after treatment with IL-6 (50ng/ml) and/or IR (C) following pre-treatment with NBD (50μMf o r2h )o r( D)A d - I κBα-DN (MOI=10). Values are
expressed as the mean+ −S.D. for three replicates. *P <0.001 compared with the control,  P <0.001 compared with IR treatment alone. (E) Myeloma cells with MnSOD overexpression or SOD2
KD were analysed for clonogenic survival and data were normalized to untreated controls. Values are expressed as the mean+ −S.D. for three replicates. *P <0.005 compared with control. (F)
Characterization of myeloma cells by immunoblotting for MnSOD overexpression or KD. The quantiﬁcation of three independent experiments, following normalization to the control, is shown above
each band. (G) qPCR analysis was performed after exposure to IL-6 or TNF-α for 10h. *P <0.01, ϕP <0.05 and  P <0.001 compared with the control.
Treatment with IL-6 and/or IR up-regulated MnSOD activity,
whichwassigniﬁcantlyinhibitedwithAd-IκBα-DN(Figure4D).
This result shows that ROS-induced NF-κB activation may be
playingadirectroleinup-regulatingMnSODactivityinmyeloma
cells.
Clonogenic assays were performed to conﬁrm the notion that
increasedMnSODexpressiondirectlyrelatestoradioresistancein
myeloma cells. MnSOD overexpression increased clonogenicity
of irradiated myeloma cells, and MnSOD KD signiﬁcantly
enhanced the radiosensitivity of both cell lines (Figure 4E).
Alterations in MnSOD protein levels in Ad-MnSOD-transduced
and stable SOD2 KD cells were conﬁrmed by immunoblotting
(Figure4F).TheenzymaticactivityofMnSODwasincreased10–
15-fold with Ad-MnSOD (compared with the Ad-CMV control),
whereas the activity was reduced 4–6-fold in SOD2 KD cells
(compared with cells expressing a scrambled control shRNA;
results not shown).
As TNF-α and IL-1β are myeloma cell pro-proliferative
cytokines that can also regulate MnSOD expression via NF-κB-
mediatedtranscription[18],therelativeabilityofIL-6andTNF-α
to induce the SOD2 mRNA expression was assessed. In myeloma
cells, treatment with IL-6 or TNF-α showed an up-regulation of
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Figure 5 IL-6 increases levels of the SOD2 mRNA and differentially regulates the mRNA levels of CAT and GPx1
Cells were treated with IL-6 (50ng/ml) and/or IR, and qPCR analysis was performed to assess SOD2, CAT and GPx1 mRNAs at 10h. The results are presented as the fold change in mRNA
expression relative to 18S mRNA, and are normalized to control untreated cells (mean of two independent experiments).  P <0.001 and #P <0.01 compared with control, ϕP <0.001, *P <0.05
and ϕP <0.005 compared with IR treatment alone.
SOD2 mRNA levels (Figure 4G). In HS-5 and HBME-1 cells,
treatment with either IL-6 or TNF-α increased SOD2 mRNA
expression (Figure 4G). For myeloma cells, lower concentrations
of IL-6 treatments (2.5 or 10 ng/ml) showed increased SOD2
mRNA expression relative to untreated controls as measured by
qPCR assay (results not shown). Taken together, the qPCR results
show that IL-6 treatment up-regulates SOD2 mRNA expression
in myeloma cells, and both IL-6 or TNF-α treatments result in an
increased expression of the SOD2 mRNA in BM accessory cells
thatmaypotentiallyaidinmyelomacellsurvivalandadaptationto
oxidative stress. Steady-state levels of GSH in HS-5 and HBME-
1 cells were measured as 70.4 and 57.2 nmol/mg of protein and
were found to be higher than GSH levels in MM.1S and 8226
cells (25.9 and 32.3 nmol/mg of protein respectively, results not
shown). Further studies are required to determine whether the
endogenous higher thiol content renders a more robust increase
in SOD2 mRNA induction in the BM accessory cells.
Effect of IL-6 and irradiation on expression of mRNAs encoding
antioxidant enzymes
In mammalian cells, the cellular defence against ROS includes
enzymatic antioxidants, such as SODs, catalase and GPxs. We
next determined if IL-6 treatment would alter IR-mediated
perturbations in these antioxidant enzymes. Treatment with IL-6
up-regulated SOD2 mRNA in all cells and IL-6 plus IR further
increasedthelevelsofSOD2transcripts(Figure5).qPCRanalysis
of the major H2O2 detoxiﬁcation enzymes, catalase and GPx-
1, showed that, in myeloma cells, catalase or GPx1 mRNA
levels were not increased with IL-6, but were increased after
combination treatment with IL-6 plus IR (Figure 5). In HS-
5 cells, treatment with IL-6 caused a robust increase in CAT
and GPx1 mRNA, which was signiﬁcantly increased with IL-
6 plus IR treatment (Figure 5). Treatment with IL-6 increased
CAT mRNA, and IL-6 plus IR induced GPx1 mRNA in HBME-1
cells (Figure 5). From these qPCR results, it can be speculated
that IL-6-mediated increases in levels of SOD2, CAT or GPx1
mRNA probably helps in normalizing the level of oxidative
stress induced by irradiation, thereby inducing radioresistance
in myeloma cells and simultaneously preserving the myeloma
cell microenvironment provided by the BM, and also secretion
of paracrine cytokines; all of these events would be crucial
in sustaining myeloma cell survival and proliferation following
irradiation.
IL-6 inhibits mitochondrial oxidant production in myeloma cells
Since MnSOD closely regulates the clearance of ROS in the
mitochondria and we observed an up-regulation of MnSOD by
IL-6 treatment, ﬂow cytometry was performed to detect IL-6-
and/or IR-induced mitochondrial oxidant generation (presumably
O2
•−) in myeloma cells [26]. For this, oxidation of the MitoSOX
Red probe (a mitochondrially targeted hydroethidine derivative
[28]) was utilized. At 36 h, treatment with IL-6 resulted in a
trend towards a decrease in endogenous levels of mitochondrial
oxidants with fold change as 0.5+ −0.1 and 0.9+ −0.1 for MM.1S
and 8226 cells respectively relative to control untreated cells (set
to 1.0). Irradiated cells showed elevated MitoSOX Red oxidation
at 36 h (fold changes were 1.3+ −0.3 and 2.7+ −0.2 for MM.1S
and 8226 cells respectively relative to untreated cells) that was
signiﬁcantly inhibited by IL-6 pre-treatment (fold changes were
0.8+ −0.3 and 1.6+ −0.2 for MM.1S and 8226 cells respectively,
Figure 6A).
Live cell imaging of MitoSOX Red oxidation using confocal
microscopy showed that, relative to the untreated control, IL-6
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Figure 6 IL-6 attenuates irradiation-induced mitochondrial oxidant
production
Myeloma cells were treated with IL-6 (50ng/ml) and/or IR, and MitoSOX-derived red
ﬂuorescence was analysed at 36h. (A) Measurement of MFI of oxidized MitoSOX Red by
ﬂow cytometry. Graphs with MFI values are shown from one experiment, and are representative
of two independent experiments. For each graph, the x axis and y axis show the percentage
of cells and MitoSOX oxidation respectively. (B) Confocal live imaging of MitoSOX Red and
MitoTracker Green. Representative confocal images of control untreated cells and cells after
IL-6 and/or IR treatments are shown. The 488nm and 594nm excitation wavelength was used
for imaging MitoTracker Green and MitoSOX Red ﬂuorescence signal respectively. Arrowheads
point at signiﬁcant alterations in MitoSOX-derived red ﬂuorescence in mitochondria of IR and
IL-6 plus IR treated myeloma cells. (C) Measurement of ﬂuorescence intensity of oxidized
MitoSOX in a plate reader assay. Cells were pre-treated without or with Z-VAD-FMK (100μM
for 2h) followed by IL-6 and/or IR treatments. Data are presented as the fold change relative
to the untreated control, and are representative of three independent experiments. *P <0.005
compared with control,  P < 0.05 compared with IR, ζP <0.005 compared with Z-VAD-FMK
and ϕP <0.001 compared with Z-VAD-FMK plus IR.
treatment resulted in a decrease in steady-state levels of
mitochondrial oxidants, whereas irradiation caused a signiﬁcant
increaseinMitoSOXRedoxidationasimagedat36 h(Figure6B).
Furthermore, compared with IR alone, IL-6 plus IR treatment
resulted in a remarkable reduction in steady-state levels of
mitochondrial oxidants (Figure 6B). The speciﬁcity of MitoSOX
oxidation was conﬁrmed by treating the cells with antimycin A
or PEG–SOD (results not shown).
Since the activation of caspases can result in feedback
ampliﬁcation of ROS production from mitochondria [40], the
pan-caspase inhibitor Z-VAD-FMK was used to block ROS
production by activated caspases, and MitoSOX oxidation was
measured at 36 h following IL-6 and/or IR treatments. As shown
in Figure 6(C), for both MM.1S and 8226 cells, irradiation
resulted in an increased steady-state level of mitochondrial O2
•−
production that was signiﬁcantly inhibited by IL-6 treatment.
Inhibition of caspase activation partly attenuated irradiation-
induced mitochondrial O2
•− production, indicating the onset of
late-phase ROS generated by caspase activation. Nevertheless,
IL-6 treatment inhibited irradiation-induced MitoSOX oxidation
in the presence of Z-VAD-FMK, conﬁrming that IL-6-mediated
early ROS is causally related to MnSOD-mediated attenuation
of late mitochondrial oxidant production in irradiated myeloma
cells. Taken together, MitoSOX Red oxidation results show that,
in myeloma cells, IL-6 treatment attenuates endogenous and
IR-induced increases in the steady-state levels of mitochondrial
oxidants that would result in increased survival of myeloma cells
to oxidative stressors.
DISCUSSION
MM remains a fatal disease, primarily owing to acquired
resistance to anti-myeloma chemotherapeutic drugs [1]. Our
previous studies have shown that combining targeted radiation
with chemotherapeutic drugs enhances the effectiveness of
radiotherapy in MM [10,20,24,41]. IL-6 is known to induce
myeloma cell proliferation and confer aggressive growth
properties and drug resistance in myeloma cells [1]. In myeloma
and B-cell lymphoma, radioresistance has been correlated with
the presence of IL-6-secreting tumour cells [42]. We previously
reported that IR induces NF-κB activation in myeloma cells
[23], and that paracrine IL-6 secretion confers radioresistance
to myeloma cells [20]. Oxidative stressors such as IR and
H2O2 have been shown to enhance IL-6 secretion by activating
NF-κB transcription [43,44]. Thus IL-6 expression in the BM
microenvironment is robust, and our published ﬁndings show that
inhibition of constitutive and therapy-induced IL-6 synthesis is
essentialforeffectivekillingofmyelomacellsbyIR.Inthepresent
study we evaluated the roles of myeloma-promoting cytokines,
with a major focus on IL-6, in adaptation to endogenous and
therapy-induced oxidative stress in myeloma and BM accessory
cells.
Pro-inﬂammatory cytokines, such as TNF-α,I L - 1 β and IL-6
have been reported to induce O2
•− production and also trigger
downstream signalling events [3,30,45]. Using ﬂuorigenic probes
(H2DCF-DA and DHE), the present study shows that IL-6 or
TNF-α treatments induce a rapid rise in pro-oxidants in myeloma
cells. With IL-6 treatment, HPLC analysis showed considerable
formation of E
+ and other DHE oxidation products. Studies are
ongoingtodeterminewhether,inmyelomacells,DHEand2-OH-
E
+ rapidly reacts with different oxidants (such as H2O2 in the
presence of haem proteins or peroxidases) and whether utilizing
SOD2 KD myeloma cells may aid in better identifying IL-6-
induced O2
•− production. Since both IL-6 and TNF-α directly
induce myeloma cell proliferation and IL-1β drives paracrine
IL-6 secretion, an increase in the production of ROS could
mediateenhancedproliferationandthedevelopmentofresistance
to oxidative stressors. Notably, when IL-6 was combined with
IR or Dex, a concerted increase in early ROS production was
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observed. Since IL-6 treatment inhibited IR- and Dex-mediated
myeloma cell death, IL-6 may play a role in the induction of
redox-regulated antioxidant pathways in MM cells. Consistent
with these ﬁndings, IL-6 has been shown to protect normal cells
from injuries induced by oxidative stress [4,5,46].
IL-6 is a pro-proliferative cytokine for myeloma cells, and
increased plasma levels of IL-6 correlates with poor prognosis
[1]. On the basis of the disease stage, the serum levels of IL-6
in myeloma patients can range from 0.01 to 0.4 ng/ml; the
actual IL-6 serum concentration can be even higher, since
circulating IL-6 also binds to soluble IL-6 receptors [47]. In
myelomatous BM, a local high concentration of IL-6 can be
reached, given that myeloma cells produce IL-6 via the autocrine
loop [48] and by adhesion with BM stromal cells, leading to
paracrineIL-6secretionbystromalcells[49].Inthepresentstudy
we have combined exogenous IL-6 (50 ng/ml) with irradiation;
however, lower concentrations of IL-6 (2.5 and 10 ng/ml) also
protected myeloma cells from irradiation-induced apoptosis,
resulted in pro-oxidant production and induced MnSOD protein
expression.TheprotectiveeffectsofIL-6oncelldeathinducedby
oxidative stressors were assessed after IL-6 pre-treatment for 6 h
mainly because IL-6 showed maximum NF-κB activation at 4 h.
Furthermore, as IL-6 is constantly present in the myeloma cell
microenvironment, IL-6 treatment was continued until samples
were collected for analysis. We plan to extend the present study
to primary human myeloma samples in the near future. However,
for ex vivo cultured primary myeloma cells, the culture medium
is supplemented with exogenous IL-6 (5 ng/ml), making the
experimental design difﬁcult.
GSH provides a major source of thiol homoeostasis and
constitutes theﬁrstlineofthecellulardefencemechanismagainst
oxidativestressors.Incancercells,increasedGSHlevelshasbeen
correlated with chemoresistance and radioresistance [33,50], and
depletion of intracellular GSH can reverse drug resistance
and improve the outcome of cancer therapies, including those for
haematological malignancies [51,52]. GSH kinetics over time
with IL-6 and TNF-α in myeloma cells show that IL-6 treatment
results in a transient early decrease in GSH levels, whereas TNF-
α treatment caused a more sustained decrease in total GSH levels
until 24 h. Along similar lines, Nakajima et al. [36] showed
that, in neuronal cells, IL-6 treatment results in increased γ-
glutamylcysteine synthetase activity, which is the rate-limiting
enzyme of GSH synthesis. Also, TNF-α treatment has been
shown to decrease the intracellular levels of GSH by formation
of mixed disulﬁdes and inhibition of the glutathione reductase
system [53,54]. Our ongoing studies will delineate how the thiol
pool in myeloma cells is perturbed in the presence of various
pro-inﬂammatory cytokines and if GSH depletion by buthionine
sulfoximine would alter NF-κB activation and the overall therapy
responses in multiple myeloma.
Previous studies have shown that under normal physiological
conditions, i.e. when cells are able to maintain redox
homoeostasis, ROS may function as intracellular signalling
molecules [55] and ROS-mediated NF-κB activation regulates
cellular redox homoeostasis [56]. NF-κB activation by oxidants
is cell-context dependent and can be increased or decreased,
depending on sequential events and concentrations of oxidants
and antioxidants [57]. Studies have shown that a reduced
intracellular environment favours NF-κB activation [38], and
redox changes mediated by TNF-α treatment can inhibit NF-
κB activity [39]. In myeloma cells, simultaneous treatment with
IL-6 and H2O2 showed increased NF-κB activation, whereas
TNF-α incombinationwithH2O2 inhibitedNF-κBactivity.TNF-
α plays a role in MM pathogenesis by up-regulating NF-κB-
induced expression of adhesion molecules on myeloma and BM
stem cells, thus increasing paracrine IL-6-mediated MM cell
growth and survival. In the present study, TNF-α was not as
effectiveasIL-6 inprotectingmyelomacellsfromH2O2-mediated
oxidative myeloma cell death. Further studies are warranted
to determine how TNF-α treatment regulates NF-κB activation
in myeloma cells in the presence of oxidative stress-inducing
therapies.
Mammalian cells possess a well-co-ordinated enzymatic
antioxidant defence system comprised principally of SODs,
catalase, peroxiredoxins and GPxs, and this system aids in
rapid defence against oxidative stress. In myeloma cells, the
present study provides evidence for NF-κB to play a role in
driving IL-6-mediated up-regulation of MnSOD expression, and
shows that IL-6 treatment leads to increases in the enzymatic
activityofMnSOD.Furthermore,IL-6-inducedNF-κBactivation
rendered radioresistance in myeloma cells. Indeed, MnSOD is a
potent protector of cancer cells against both chemotherapy and
radiotherapy [58,59]. Also, TNF-α,I L - 1 β and IL-6 treatments
can increase MnSOD expression [60–63], and NF-κB-mediated
SOD2 transcription has been associated with cytokine and IR
treatments [18,30,31]. Previous studies have identiﬁed a clear
role of NF-κBi nIL6 gene expression [64]. Further studies
will determine whether a feed-forward loop of NF-κBo nI L - 6
signalling is responsible for a stronger effect on MnSOD activity.
Indeed, improved myeloma cell cytotoxicity was seen when 2-
methoxyestradiol,aproposedinhibitorofMnSOD,wascombined
with ROS-generating drugs, such as bortezomib [65] and arsenic
trioxide [66]. In myeloma cells, IL-6-mediated MnSOD up-
regulation was partially coupled with increases in the mRNA
levels of CAT and GPx1. Thus induction of MnSOD by IL-6
treatmentmaypotentiallyleadtoatransientaccumulationofH2O2
in myeloma cells that may be alleviated by the up-regulation of
hydroperoxide-metabolizing systems.
During basal steady-state metabolism, ROS are generated
primarily from mitochondrial respiratory chains, and mito-
chondria are believed to serve as a nodal control point that
regulates apoptosis. Furthermore, antioxidant systems, such as
glutathione/GPx and MnSOD, work dynamically to regulate any
endogenous and/or therapy-induced elevation of mitochondrial
ROS, and to inhibit apoptosis initiated by oxidative damage to
mitochondria. The present study shows that treatment with IL-6
decreases IR-induced late mitochondrial pro-oxidant generation
in myeloma cells, suggesting that, besides providing pro-
proliferative signalling, IL-6 may inhibit IR- and chemotherapy-
induced oxidative damage to the mitochondria of myeloma cells.
In conclusion, the resistance of several haemopoietic cancers
to cytotoxic chemotherapy and radiotherapy is well established
but not understood. The present study provides evidence to
support a role for IL-6 in myeloma therapy resistance and
proposesamechanisminvolvingNF-κB-dependentup-regulation
of MnSOD. Our results provide a novel biochemical rationale
for combining MnSOD inhibition with oxidative stress-inducing
therapeutic agents, which paradoxically also stimulate IL-6 and
thereby counteract oxidative stress, for the development of an
effective new therapeutic strategy for treating MM.
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EXPERIMENTAL
Cytotoxicity analysis using MTT assay
Cells were seeded in 96-well plates and a subset was pretreated
with IL-6 (50 ng/ml). Cells were subsequently treated with
Dex (1 μM) or irradiation (6 Gy) and cultured for 48 h. Cell
viability and proliferation was assessed with MTT dye using a
commercially available kit (A.T.C.C.) [1,2].
HPLC analysis of DHE oxidation products
For quantitative analysis of DHE oxidation products, HPLC
electrochemical analysis was performed [3,4]. Brieﬂy, 8226 cells
(1×10
6 cells/condition) were preloaded with DHE (10 μMa t
37◦C for 30 min), followed by treatment with IL-6 (50 ng/ml)
or antimycin A (10 μM), or no treatment (control) for 30 min.
Cells were centrifuged, washed with PBS, counted and stored at
−80◦C. On the day of HPLC analysis, samples were prepared
as described by Zielonka et al. [3]. An ESA CoulArray system
with a Phenomenex 250 mm×4.6 mm Synergi 4 μmP o l a r - R P
80A column was used to quantify oxidation products of DHE.
Figure S1 Treatment with IL-6 or IR induces early ROS production in MM.1S myeloma cells
MM.1S cells were treated for 0.5, 1 or 2 h with (A)I L - 6o r( B) IR, and DHE oxidation was measured by ﬂow cytometry. Graphs with MFI values are shown from one experiment, and are representative
oftwoexperiments.(C)MyelomacellswerepretreatedwithoutorwithNAC,andthenincubatedwithIL-6(1,2.5,10or50ng/ml)andH2DCF-DAoxidationwasmeasuredat2 h.*P < 0.05compared
with control (no IL-6 treatment).
Quantiﬁcation of 2-OH-E
+ was determined using the 200,
280 and 365 mV channels, and E
+, using the 280, 365, 400,
450and500mVchannelsandstandardcurveswerepreparedfrom
authentic standards. HPLC data were adjusted for cell numbers
and dilutions made during sample processing and analysis.
NF-κB assay
The transcriptional activity of NF-κB was measured using an
ELISA-based assay (TransAM NF-κB p65 transcription factor
assay kit) as described previously [5]. Cells were infected with or
without Ad-IκBα-DN for 48 h and exposed to 6-Gy IR or sham
IR.Nuclearextractswereprepared2 hafterIRandincubatedwith
immobilized oligonucleotide containing a consensus-binding site
for the p65 subunit of NF-κB or the control oligonucleotide.
Binding was detected by a primary antibody speciﬁc for p65
followed by incubation with anti-IgG antibody conjugated to
horseradish peroxidase. The product was quantiﬁed at 450 nm.
Absorbance of the untreated cells was set to 1 and the fold
activation/repression in the NF-κB activity was evaluated after
normalizing the samples for cellular protein content.
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Figure S2 2-OH-E+, the superoxide-derived oxidation product of DHE, is
observed with HPLC
RepresentativeHPLCchromatogramsfrom8226cellsincubatedwithDHEandthentreatedwith
antimycin A (Ant A) or untreated (control; Cont) for an additional 30min. For simplicity, one
channel (365 mV) of the eight channels monitored is presented to illustrate retention times
and relative intensities of the various oxidation products of DHE found in cell extracts. HE is
dihydroethidine, 2-OH-E+ is the O2
•− -speciﬁc 2-hydroxyethidium product, and E+ is the
non-speciﬁctwo-electronoxidationproduct,ethidium.HPLCwithelectrochemicaldetectionwas
performedusinganESACoulArraysystemwithaPhenomenex250mm×4.6mmSynergi4μm
Polar-RP 80A column. Quantiﬁcation of 2-OH-E+ was determined using the 200, 280 and 365
mVchannels,andE+ wasdeterminedusingthe280,365,400,450and500mVchannels,and
standard curves were prepared from authentic standards. The Table (inset) provides estimates
of net rates of accumulation of the oxidation products in cells during experiments on a per cell
basis; zmol is zeptomoles (10−21).
Figure S3 Dex induces early ROS production in MM.1S myeloma cells and
IL-6 protects myeloma cells against Dex-induced cytotoxicity
(A) MM.1S cells were treated for 0.5, 1 or 2h with Dex and DHE oxidation was measured by
ﬂow cytometry. For each graph depicting MFI, the x axis and y axis show the percentage of
cells and DHE oxidation respectively. MFI values are shown from one experiment. (B) The MTT
cell viability assay was performed after treatment with IL-6 and/or Dex. The data are expressed
as the percentage of live cells relative to the untreated control, which is set at 100. *P < 0.05
compared with control, and ζP < 0.01 and  P < 0.0001 compared with Dex.
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Figure S4 IL-6 treatment increases MnSOD expression and NBD and Ad-IκBα-DN inhibit NF-κB activity in myeloma cells
MM.1Sand8226cellsweretreatedwith(A)IL-6(2.5or10ng/ml)andwhole-cellextractwasprobedforMnSODexpressionat24h.TheratiobetweenMnSODandtubulinlevels,afternormalization
to untreated control, is shown above each band. Myeloma cells were treated with IL-6 (50ng/ml) and/or IR (B) after pretreatment without or with NBD (50μM for 2h). Luc activity was measured at
4 h. Values are depicted as the fold change in mean RLU+ −S.D., n=3, normalized to protein concentration. *P < 0.01 compared with IL-6,  P < 0.01 compared with IR treatment alone or IL-6
plus IR. Myeloma cells were treated with IL-6 (50ng/ml) and/or IR (C) after 48h of transduction with Ad-IκBα-DN (MOI=10). The DNA-binding activity of NF-κB was analysed at 2h in nuclear
extracts. The results are presented as the fold repression or activation of NF-κB activity compared with control. *P < 0.01 and  P < 0.01 compared with IR treatment alone. (D) Myeloma cells
were transduced with Ad-IκBα-DN (MOI=10), whole-cell extract was made at 48h and probed with an antibody against IκBα or tubulin.
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